Hosted on MSN26d
JCR Pharmaceuticals Gains Orphan Drug Status in Japan
JCR Pharmaceuticals Co., Ltd. (JP ... Newsletter JCR Pharmaceuticals has been granted orphan drug designation in Japan for JR-441, aimed at treating the rare Mucopolysaccharidosis Type IIIA.
Hosted on MSN1mon
New Drug Application Submitted in Japan for Verrica Pharmaceuticals’ TO-208
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that its partner, Torii Pharmaceutical Co. Ltd., has submitted a New Drug Application (NDA) in Japan for TO-208 ...
Biocon share rises 4% as arm gets Japan's PMDA approval for Psoriasis drug
The rise in Biocon stock was also fuelled after Jefferies upgraded the stock to 'Buy', and raised the target to Rs 400 ...
Business Wire1mon
JCR Pharmaceuticals Initiates Phase III Clinical Trial of JR-142 in Japan, a Long-Acting Growth Hormone Therapy
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) today announced that the first patient has been dosed in the Phase III clinical trial of JR-142 (INN ...
Nasdaq26d
JCR Pharmaceuticals Gains Orphan Drug Status in Japan
all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter JCR Pharmaceuticals has been granted orphan drug designation in ...